NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 8, 2005 • Volume 2 / Number 43 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial


"Understanding NCI" Teleconference

NCI's Office of Liaison Activities will hold an "Understanding NCI" teleconference on the NCI Mouse Models of Human Cancers Consortium November 9 at 3:00 p.m., EST. To join the call, dial -800-857-6584 and enter pass code 4683#.

New Targeted Therapy for Solid Tumors and Lymphomas

Name of the Trial
Phase I Study of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Patients with an Advanced Solid Tumor or Lymphoma (NCI-04-C-0218). See the protocol summary at http://cancer.gov/clinicaltrials/NCI-04-C-0218.

Principal Investigator
Dr. Martin Gutierrez, NCI Center for Cancer Research

Why Is This Trial Important?
Heat shock proteins (HSPs) are found in every cell of the body. HSPs help cells survive stressful conditions (including heat, cold, nutrient starvation, and oxygen deprivation) by protecting other proteins. Under nonstressful conditions, HSPs help proteins achieve and maintain their proper shape. Researchers at NCI are investigating a particular HSP, called HSP-90, as a target for cancer therapy. Many of the proteins implicated in cancer development need HSP-90 to help them achieve their correct functional shape and cellular location.

In this trial, researchers are studying 17-DMAG, an HSP-90 inhibitor developed by NCI, to see if it can help prevent cancer cells from growing in patients with solid tumors or lymphomas. The trial will also be used to determine the maximum dose of 17-DMAG that can be given to patients and examine what side effects the drug may cause.

"Preclinical research results suggest that inhibiting HSP-90 will alter many of the protein pathways in tumor cells and may result in tumor cell death," said Dr. Gutierrez. "This is the first test of 17-DMAG in humans, and so far, the drug has been well tolerated.

"We think that 17-DMAG's mode of action may represent an important new approach in the treatment of many types of cancer."

Who Can Join This Trial?
Researchers seek to enroll 40 patients aged 18 or over with either solid tumor malignancy or lymphoma that is metastatic or inoperable, and for which standard curative or palliative measures do not exist or are associated with minimal survival benefit. See the full list of eligibility criteria at http://cancer.gov/clinicaltrials/NCI-04-C-0218.

Where Is This Trial Taking Place?
The study will be done at the NIH Clinical Center in Bethesda, Md.

Contact Information
Contact the NCI Clinical Studies Support Center (CSSC) at 1-888-NCI-1937. The call is toll free and confidential.


An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.